

REMARKS

Claims 1-10 are presented in this application. In this amendment, claims 1, 3, 4-6, and 9 have been amended. Claims 1, 3, 4-6, and 9 have been amended to place them in form appropriate to US practice and to remove multiple dependencies for the purpose of reducing fees. Claim 10 has been cancelled.


Applicants have amended the specification for purposes of adding the priority information. Further, appropriate headings have been inserted in accordance to 37 CFR 1.77. Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Entry of the amendment prior to the examination of the application and calculation of the filing fee is respectfully requested.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,



Karen L. Prus
Attorney for Applicant
Registration No. 39,337

Date: February 28, 2006
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-2192
Facsimile: 919-483-7988

Express Mail Label No.: EV332131204US

Date of Mailing: 2/28/2006

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.


Patty Wilson